{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"45"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"On-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"51"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"title":"Post-treatment survival follow-up deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"45"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"45"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"55"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"On-treatment deaths were collected from first dose of study medication to 30 days after study drug discontinuation, for a maximum duration of 85 months. Post-treatment survival follow-up deaths were collected from day 31 after last dose of first dose of study medication, up to 92 months. All deaths refer to the sum of on-treatment deaths and post-treatment survival follow-up deaths.","groups":[{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG000","title":"Anaplastic Thyroid Cancer (ATC)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG001","title":"Biliary Tract Cancer (BTC)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG002","title":"Gastrointestinal Stromal Tumor (GIST)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG003","title":"Low Grade (WHO G1/G2) Glioma (LGG)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG004","title":"High Grade (WHO G3/G4) Glioma (HGG)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG005","title":"Adenocarcinoma of the Small Intestine (ASI)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG006","title":"Hairy Cell Leukemia (HCL)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG007","title":"Multiple Myeloma (MM)"}],"paramType":"NUMBER","populationDescription":"All-treated Subjects (ATS) population - Primary and expansion cohort combined","reportingStatus":"POSTED","timeFrame":"On-treatment deaths: Up to 85 months. Post-treatment survival follow-up deaths: Up to 92 months.","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}